Boehringer Ingelheim and OSE Immunotherapeutics advance clinical development of first-in-class SIRPa cancer immunology treatment BI 770371
Download the publications
You confirm that you have read our privacy policy. You can unsubscribe at any time by using the unsubscribe links.